Natera, Inc. Common Stock
NTRANatera, Inc. is a biotechnology company specializing in genetic testing and diagnostics. It develops and offers advanced cell-free DNA testing services for reproductive health, oncology, organ transplant monitoring, and rare disorders. Natera's innovative approach includes non-invasive prenatal testing (NIPT) and other laboratory-based genetic assays to help clinicians and patients make informed medical decisions.
Company News
The global Non-Invasive Prenatal Testing (NIPT) market is projected to grow at a CAGR of 17.01% from 2024 to 2031, reaching USD 9.83 billion from USD 2.8 billion in 2024. Growth is driven by rising demand for early fetal detection, advancements in next-generation sequencing technology, and increased adoption of safer prenatal testing methods. How...
The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. Nort...
Natera presented research showing its Signatera Genome test can effectively predict distant recurrence risk in stage II-III breast cancer patients by measuring molecular residual disease (MRD) status after treatment.
Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.
Natera acquired Foresight Diagnostics for $275 million upfront with potential additional $175 million in earnouts, strengthening its precision oncology capabilities through advanced circulating tumor DNA testing technology.
